News from Target Ovarian Cancer
14.06.13 In the news: Yesterday the US Supreme Court ruled that human genes may not be patented. Target Ovarian Cancer welcomes important legal breakthrough in the United States surrounding testing for familial breast and ovarian cancer
10.06.13 Bumper weekend of fundraising activity raises over £22,000 Target Ovarian Cancer's teams in both the Nightrider weekend and Broadgate Tower abseil have raised an incredible £22,000 for the charity.
06.06.13 The inequity of access to Avastin discussed at the All Party Parliamentary Group on Ovarian Cancer MPs heard yesterday about fears over the future funding of Avastin in England, and the challenges facing women around the UK in terms of accessing the drug, given recent negative decisions by both the National Institute of Health and Care Excellence (NICE) and the Scottish Medicines Consortium...
03.06.13 In the news: Votrient (pazopanib) improves progression-free survival in Phase III trial of women with ovarian cancer. Data presented at the 2013 Annual Meeting of the American Society of Clinical Oncology this weekend shows that the drug Votrient (pazopanib), developed by GlaxoSmithKine, improves progression-free survival for women with ovarian cancer by an average of almost six months.